The Brazil vaccine market was valued at USD 3.92 Billion in 2024, driven by the surge in infectious disease cases and rising public-private partnerships in the region. The market is anticipated to grow at a CAGR of 6.10% during the forecast period of 2025-2034, with the values likely to reach USD 7.09 Billion by 2034. The market is propelled by the growing public health infrastructure and high vaccination acceptance rates. Expanding adult vaccination programs and advancements in mRNA vaccine technologies are expected to fuel demand in the forecast period.

In Brazil Aquaculture Vaccines Market, offering valuable insights, key market trends, competitive landscape, and future outlook to support strategic decision.

In 2024, the Brazilian vaccine market decreased by -37.1% to $1.1B, falling for the third year in a row after four years of growth. Over the period under review, consumption, however, recorded a tangible expansion. As a result, consumption reached the peak level of $4.3B. From 2022 to 2024, the growth of the market failed to regain momentum.

Brazil Veterinary Vaccines Market was valued at USD 1.45 Billion in 2024 and is expected to reach USD 2.48 Billion in the forecast period with a CAGR of 9.36% through 2030.

Pages	84
Market Size	2024: USD 1.45 Billion
Forecast Market Size	2030: USD 2.48 Billion
CAGR	2025-2030: 9.36%
Fastest Growing Segment	Attenuated Live Vaccines
Largest Market	South-East
Key Players	1. Merck & Co., Inc. 2. Elanco Animal Health Inc. 3. Boehringer Ingelheim International GmbH 4. Ceva Animal Health, LLC 5. Zoetis Inc. 6. Dechra Pharmaceuticals Plc 7. Phibro Animal Health Corporation 8. Biogénesis Bagó S.A. 9. Ouro Fino Saúde Animal Participações SA 10. Virbac S.A.

The Brazil Vaccines market is anticipated to grow at more than 7% CAGR from 2023–2028.

Brazil Diphtheria, Pertussis, And Tetanus Vaccine Market is expected to grow during 2025-2031

The Global Rabies Veterinary Vaccines Market is expected to grow at a CAGR of approximately 7.5% from 2024 to 2034

Uncover Market Research Intellect's latest report_name, valued at current_value in 2024, expected to rise to forecast_value by 2033 at a CAGR of cagr_value from 2026 to 2033.

Brazil Dendritic Cell Cancer Vaccine Market Size was valued at USD 20.3 Billion in 2024 and is projected to reach USD 35.3 Billion by 2031, growing at a CAGR of 7.9% from 2024 to 2031.

Brazil Dendritic Cell Cancer Vaccine Market Drivers

Rising Prevalence of Cancer: The global rise in cancer cases is a major driver for the dendritic cell cancer vaccine market. According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, with cases expected to increase significantly in the coming decades. This growing burden emphasizes the need for more effective and innovative treatments like dendritic cell cancer vaccines.

Advancements in Immunotherapy: Immunotherapy has transformed cancer treatment by leveraging the body's immune system to target and eliminate cancer cells. Dendritic cell vaccines, which stimulate a patient’s immune system by presenting tumor antigens, represent a cutting-edge approach in this field. Ongoing research and technological advancements have improved the efficacy, safety, and scalability of these vaccines, driving market growth.

The Brazil Veterinary Vaccines Market size was valued at USD 10.38 million in 2023 and is projected to reach USD 18.45 million by 2032, exhibiting a CAGR of 6.4 % during the forecasts period. It refers to the process of manufacturing, marketing and supply of vaccines in the Brazil for the treatment of animal ailments. As discussed these vaccines are crucial for livestock, poultry, pets, aquaculture to ensure the well-being of animals to prevent the spreading of zoonosis. Some of applications are involved in commercial production of crops and animal husbandry, pet shops, vet shops and clinics. Stringent trends triggering this market embrace development of the livestock farming, more demand for animals for companionship, and enhanced concern towards animal well being. Also, there is a tendency for strange vaccines like recombinant and DNA vaccines and even there is a concentration on producing animal vaccines through government support to safeguard the food chain.

Brazil Veterinary Vaccines Market is driven by increasing demand for animal-derived food products, rising pet ownership, and advancements in vaccine technology.

After four years of growth, the Brazilian veterinary medicine vaccines market decreased by -2.5% to $480M in 2024. Over the period under review, the total consumption indicated modest growth from 2012 to 2024: its value increased at an average annual rate of +1.5% over the last twelve years. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2024 figures, consumption increased by +64.4% against 2019 indices.

Brazil Pediatric Vaccines Market growth is driven by increasing demand for vaccines, government support for immunization programs, and technological advancements in vaccine formulations and delivery systems.

As of August 13, 2024 most Latin American and Caribbean countries had started the COVID-19 vaccination process. While Brazil had administered around 486 million doses of the vaccine, Mexico had applied approximately 223 million doses. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Access South America Pneumococcal Vaccines Industry Overview which includes South America country analysis of (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America), market split by Vaccine Type, Product Type, Sector, Distribution Channel

According to Cognitive Market Research, the global Yellow Fever Vaccine market size will be USD 4528.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 5.50% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 1811.40 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1358.55 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 1041.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 226.43 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 90.57 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.
The Sylvatic Yellow Fever category is the fastest-growing segment of the Yellow Fever Vaccine industry

Market Dynamics of Yellow Fever Vaccine Market

Key Drivers for Yellow Fever Vaccine Market

Rising Incidence of Yellow Fever to Boost Market Growth

Yellow fever is a potentially fatal viral disease spread by infected mosquitoes. According to the World Health Organization (WHO), as of 2023, 34 countries in Africa and 13 in Central and South America are either endemic or have endemic regions for yellow fever. Between August 26 and November 29, 2022, 22 additional confirmed cases were reported across ten countries. However, after a retrospective review, only seven new confirmed cases and one death were identified. Since 2021, in the WHO African Region, a total of 203 confirmed cases and 252 probable cases of yellow fever have been reported, with 40 deaths, resulting in a case fatality rate (CFR) of 9%. Among the confirmed cases, 23 deaths were recorded, reflecting a CFR of 11%. The high CFR among confirmed cases remained consistent, with 17 deaths (11%) in 2021 and six deaths (12%) in 2022. This increasing disease burden is driving significant demand for yellow fever vaccines, especially in endemic areas. Recent severe outbreaks in Brazil, Angola, and the Democratic Republic of Congo have intensified global awareness and the need for preventive measures, further stimulating the vaccine market.

Expansion of Vaccination Programs to Drive Market Growth

In 2017, the WHO, in collaboration with UNICEF and Gavi, the Vaccine Alliance, launched the EYE Strategy to protect at-risk populations in 40 countries across Africa and the Americas through mass vaccination campaigns and by ensuring a sustainable vaccine supply. Since the start of the current outbreak (2021 to December 7, 2022), a total of 4,385,320 people have been vaccinated in five countries—Cameroon, the Central African Republic, Chad, Ghana, and Kenya—through the ICG-supported response. A reactive campaign in Kembe Satema, Central African Republic, from November 2 to 19, 2022, achieved 101.7% coverage, while a campaign in Bambari, which ended on November 23, 2022, reached 87.7% coverage based on preliminary results. These efforts have accelerated vaccine deployment and expanded immunization programs, providing growth opportunities for vaccine manufacturers. Additionally, many countries in yellow fever-endemic regions have incorporated the vaccine into their national immunization schedules, ensuring steady demand. In several African and South American nations, yellow fever vaccination is mandatory for children, further boosting the market.

Restraint Factor for the Yellow Fever Vaccine Market

Vaccine Supply Shortages and High-Cost Will Limit Market Growth

Yellow fever vaccine production is concentrated among a limited number of manufacturers, leading to supply bottlenecks. This has caused periodic shortages, especially during large-scale outbreaks when demand surges. The production of the live-attenuated vaccine is complex, relying on chicken embryos for cultivation, which limits the ability to rapidly scale up production. In sudden outbreaks, vaccine demand often exceeds supply. The global stockpile maintained by the World Health Organization (WHO) is sometimes insufficient t...

Snapshot img

Vaccine Research Market Size 2024-2028

The vaccine research market size is forecast to increase by USD 21.4 billion, at a CAGR of 10.84% between 2023 and 2028.

The market is driven by the high prevalence of infectious diseases worldwide, necessitating the continuous development of new and effective vaccines. The adoption of artificial intelligence (AI) in vaccine research is a significant trend, accelerating the R&D process and enabling the discovery of potential vaccine candidates more efficiently. However, the market faces substantial challenges, including the high cost of vaccine research, development, and manufacturing, which can hinder the entry of new players and limit the market's growth potential. Companies seeking to capitalize on market opportunities must navigate these challenges effectively, focusing on cost reduction strategies and collaborations to share resources and expertise.
Additionally, staying abreast of the latest technological advancements in vaccine research, such as AI and gene editing, can provide a competitive edge in this dynamic market.

What will be the Size of the Vaccine Research Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2018-2022 and forecasts 2024-2028 - in the full report.
Request Free Sample

The market continues to evolve, driven by the ongoing need for epidemic and pandemic preparedness. This dynamic landscape encompasses various sectors, including cold chain technology, public health, drug discovery, and inactivated vaccines. In this context, continuous research and development efforts are underway to address the challenges of supply chain management, manufacturing processes, and regulatory approval. In the realm of inactivated vaccines, in-vivo studies and in-vitro experiments are integral to understanding their efficacy and safety. Meanwhile, conjugate vaccines and viral vectors are gaining prominence in disease models, offering potential solutions to antigenic shift and drift. Manufacturing processes are being refined through the adoption of needle-free delivery systems and advances in quality control.

Regulatory approval processes are also undergoing transformation, with data analysis playing a crucial role in ensuring vaccine safety and efficacy. Moreover, the market is witnessing the emergence of next-generation sequencing, which is revolutionizing the understanding of disease surveillance and vaccine efficacy trials. The ongoing research in this field is also addressing concerns related to long-term effects, vaccine hesitancy, and variant-specific vaccines. The market's evolution is further influenced by the ongoing development of DNA vaccines, RNA vaccines, and recombinant vaccines, which are undergoing various phases of clinical trials. The importance of animal models and immunization schedules in the context of herd immunity and global health is also being emphasized.

As the market continues to unfold, it is essential to remain attuned to the evolving patterns and applications across various sectors. The ongoing research in this field is critical to addressing the challenges of infectious diseases and ensuring public health.

How is this Vaccine Research Industry segmented?

The vaccine research industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Public
  Private


Age Group

  Pediatric
  Adult


Technology

  Recombinant Vaccines
  mRNA Vaccines
  Subunit Vaccines
  Live-Attenuated Vaccines
  Inactivated Vaccines
  Viral Vector Vaccines
  Conjugate Vaccines
  Toxoid Vaccines
  Adjuvants


Disease Type

  Infectious Diseases
  Cancer
  Autoimmune Diseases
  Allergies
  Neurological Disorders


Research Phase

  Preclinical Research
  Clinical Trials (Phase I, Phase II, Phase III)
  Discovery & Development


End-User

  Pharmaceutical & Biotechnology Companies
  Academic & Research Institutions
  Contract Research Organizations (CROs)
  Government Agencies


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  Middle East and Africa

    Egypt
    KSA
    Oman
    UAE


  APAC

    China
    India
    Japan


  South America

    Argentina
    Brazil


  Rest of World (ROW)

By End-user Insights

The public segment is estimated to witness significant growth during the forecast period.

In response to the global health crisis caused by the COVID-19 pandemic, governments have significantly invested in vaccine research and development. Institutions like the US National Institute of Allergy and Infectious Diseases (NIAID) and the US National Institutes of Health (NIH) have been at the forefront of this endeavor. The research process involves various

The global Dengue Vaccines Market is expected to be reach USD 90.0 million in 2025 and is likely to expand up to approximately USD 199.9 million by the end of 2035. The sales are believed to rise with a CAGR of 8.3% during the period of 2025 to 2035.

Metric	Value
Industry Size (2025E)	USD 90.0 million
Industry Value (2035F)	USD 199.9 million
CAGR (2025 to 2035)	8.3%

Country-wise Outlook

Country	CAGR (2025 to 2035)
Brazil	7.6%

Country	CAGR (2025 to 2035)
UK	7.1%

Country	CAGR (2025 to 2035)
France	5.1%

Country	CAGR (2025 to 2035)
Indonesia	10.2%

Country	CAGR (2025 to 2035)
Thailand	13.1%

Competitive Outlook

Company Name	Estimated Market Share (%)
Sanofi	5-10%
Takeda Pharmaceuticals	90-95%

In Africa Paediatric Vaccine Market was is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.8% from 2023 to 2032.

Introduction

The Global Animal Vaccines Market is projected to reach approximately USD 35 billion by 2033, rising from USD 14 billion in 2023. This growth is expected at a Compound Annual Growth Rate (CAGR) of 9.6% from 2024 to 2033. Several factors are driving this expansion, including rising disease incidences, government initiatives, and technological advancements.

The increasing prevalence of animal diseases has significantly heightened the demand for vaccines. For instance, the Netherlands introduced a poultry vaccination program to combat bird flu, following successful field trials. This initiative aims to control the spread of avian influenza, which has negatively impacted global poultry populations and contributed to rising egg prices. Effective vaccination strategies are becoming crucial to mitigate economic losses and improve animal welfare.

Government funding has also played a vital role in expanding the animal vaccines market. The U.S. government has allocated USD 72 million to companies like Sanofi, GSK, and CSL Ltd to enhance bird flu vaccine production. This investment is expected to double the U.S. vaccine supply to 10 million doses by early 2025. Such proactive steps are essential to ensure effective disease control measures and secure global food supplies.

Technological advancements have significantly improved vaccine development. The adoption of recombinant gene technology has led to the creation of more effective vaccines with reduced side effects. These innovations have improved mortality rates in livestock and enhanced the effectiveness of preventive measures. Modern vaccines are now designed to address specific pathogens, reducing the spread of contagious diseases.

The expanding livestock industry has further fueled the demand for vaccines. Growing meat consumption, particularly in developing nations, has increased livestock production. Consequently, ensuring animal health through vaccination is essential to maintain sustainable food production. Additionally, private sector investments are driving growth in this sector. For example, Beep Saude, a mobile vaccine provider in Brazil, recently secured 100 million reais to expand its services, indicating strong market demand.

In conclusion, the animal vaccines market is poised for substantial growth, driven by rising disease outbreaks, government investments, technological innovations, and increased demand for livestock products. The combined efforts of public and private sectors are expected to shape the market's trajectory, ensuring enhanced animal health and improved food security worldwide.

https://market.us/wp-content/uploads/2024/05/Animal-Vaccines-Market-Size.jpg" alt="Animal Vaccines Market Size">